DEAR PEOPLE’S PHARMACY: I have been taking prednisone since 2008 for an autoimmune disease, and I may spend the rest of my ...

Each bisphosphonate registration trial enrolled 3000 to 7500 patients and was powered for the demonstration of fracture efficacy, whereas the long-term extension studies, ...

A 67-year-old woman is referred by her primary care physician for treatment of osteoporosis and progressive bone loss. Oral bisphosphonate therapy is recommended. Bisphosphonates suppress bone reso ...

In the CPRD cohort, researchers observed 5,234 deaths among bisphosphonate users (27%) during 45,690 person-years of follow-up, and 85,105 deaths among nonusers (40%) during 915,867 person-years ...

Long-term bisphosphonate therapy for osteoporosis can change bones at the microscopic level to make them more susceptible to the rare catastrophic transverse breaks known as atypical femoral ...

Looking at 10 randomized clinical trials including 23,384 women, 12.4 months (95% CI 6.3-18.4 months) on bisphosphonate therapy was the time needed to avoid one nonvertebral fracture per 100 ...

With the risk of ONJ for oral bisphosphonate users apparently falling somewhere in the 1 in 100,000 patient-treatment-years range, the risk-benefit analysis is an easy one, Shane said.

Spet. 9, 2011— -- ADELPHI, Md. -- A U.S. Food and Drug Administration advisory committee wants the agency to limit the duration of bisphosphonate therapy for treatment of osteoporosis, but ...

January 8, 2008 — Temporary or permanent discontinuation of bisphosphonate therapy should be considered in patients who present with severe musculoskeletal pain, the US Food and Drug ...

Long-term bisphosphonate use is associated with a rare risk of osteonecrosis of the jaw or atypical femoral fractures. At the same time, bisphosphonates continue to have a therapeutic effect after ...

Bisphosphonate-mediated inhibition of osteoclast function seems to decrease bone resorption and inhibit normal bone turnover remodelling. Bone resorption and remodelling play an essential role in ...

Bisphosphonate associated osteonecrosis of the jaws (BONJ) has been well documented recently in relation to intravenous preparations of the drug. These are most commonly used as part of the ...